Trial
NCT06822517
A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Ventus Therapeutics U.S., Inc.
Collaborators
—
Condition
Parkinson Disease
Intervention
VENT-02
Why stopped
Sponsor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-29